Table of Content


Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Hemophilia treatment industry 360 degree synopsis, 2017- 2028
2.1.1 Business trends
2.1.2 Disease trends
2.1.3 Product trends
2.1.4 Patient trends
2.1.5 Treatment trends
2.1.6 Therapy trends
2.1.7 Drug class trends
2.1.8 Route of administration trends
2.1.9 End-use trends
2.1.10 Regional trends
Chapter 3 Hemophilia Treatment Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028 (USD Million)
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Growing prevalence of hemophilia across the globe
3.3.1.2 Rise in favourable government initiatives
3.3.1.3 Increase in R&D and new product development
3.3.1.4 Growing adoption of prophylaxis treatment
3.3.1.5 Upsurge in hemophilia prevalence in new-borns
3.3.1.6 Introduction of new drug launches
3.3.1.7 Rise in hemophilia inhibitors
3.3.2 Industry pitfalls & challenges
3.3.2.1 High cost associated with hemophilia treatment
3.3.2.2 Lack of awareness in developing and under-developed regions
3.3.2.3 Low adoption rates of technologically advanced products
3.4 Growth potential analysis
3.4.1 By disease
3.4.2 By product
3.4.3 By patient
3.4.4 By treatment
3.4.5 By therapy
3.4.6 By drug class
3.4.7 By route of administration
3.4.8 By end-use
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2021
3.7.1 Competitive matrix analysis, 2021
3.8 PESTEL analysis
Chapter 4 Hemophilia Treatment Market, By Disease
4.1 Key segment trends
4.2 Hemophilia A
4.2.1 Market size, by region, 2017 - 2028 (USD Million)
4.2.2 Severe
4.2.2.1 Market size, by region, 2017 - 2028 (USD Million)
4.2.3 Moderate
4.2.3.1 Market size, by region, 2017 - 2028 (USD Million)
4.2.4 Mild
4.2.4.1 Market size, by region, 2017 - 2028 (USD Million)
4.3 Hemophilia B
4.3.1 Market size, by region, 2017 - 2028 (USD Million)
4.3.2 Severe
4.3.2.1 Market size, by region, 2017 - 2028 (USD Million)
4.3.3 Moderate
4.3.3.1 Market size, by region, 2017 - 2028 (USD Million)
4.3.4 Mild
4.3.4.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 5 Hemophilia Treatment Market, By Product
5.1 Key segment trends
5.2 Recombinant Factor Concentrates
5.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.2.2 Factor VIII
5.2.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.2.3 Factor IX
5.2.3.1 Market size, by region, 2017 - 2028 (USD Million)
5.3 Plasma-derived Factor Concentrates
5.3.1 Market size, by region, 2017 - 2028 (USD Million)
5.3.2 Factor VIII
5.3.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.3.3 Factor IX
5.3.3.1 Market size, by region, 2017 - 2028 (USD Million)
5.4 Extended Half-life Products
5.4.1 Market size, by region, 2017 - 2028 (USD Million)
5.4.2 Factor VIII
5.4.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.4.3 Factor IX
5.4.3.1 Market size, by region, 2017 - 2028 (USD Million)
5.5 Others
5.5.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 6 Hemophilia Treatment Market, By Patient
6.1 Key segment trends
6.2 Pediatric
6.2.1 Market size, by region, 2017 - 2028 (USD Million)
6.2.2 0 to 4 years
6.2.2.1 Market size, by region, 2017 - 2028 (USD Million)
6.2.3 5 to 13 years
6.2.3.1 Market size, by region, 2017 - 2028 (USD Million)
6.2.4 14 to 18 years
6.2.4.1 Market size, by region, 2017 - 2028 (USD Million)
6.3 Adult
6.3.1 Market size, by region, 2017 - 2028 (USD Million)
6.3.2 19 to 44
6.3.2.1 Market size, by region, 2017 - 2028 (USD Million)
6.3.3 45+
6.3.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 7 Hemophilia Treatment Market, By Treatment
7.1 Key segment trends
7.2 Prophylaxis
7.2.1 Market size, by region, 2017 - 2028 (USD Million)
7.3 On Demand
7.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 8 Hemophilia Treatment Market, By Therapy
8.1 Key segment trends
8.2 Factor Replacement Therapy
8.2.1 Market size, by region, 2017 - 2028 (USD Million)
8.3 Non-factor Replacement Therapy
8.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 9 Hemophilia Treatment Market, By Drug Class
9.1 Key segment trends
9.2 Vasopressin
9.2.1 Market size, by region, 2017 - 2028 (USD Million)
9.3 Coagulation Factors
9.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 10 Hemophilia Treatment Market, By Route of Administration
10.1 Key segment trends
10.2 Injectable
10.2.1 Market size, by region, 2017 - 2028 (USD Million)
10.3 Nasal Spray
10.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 11 Hemophilia Treatment Market, By End-use
11.1 Key segment trends
11.2 Hospitals
11.2.1 Market size, by region, 2017 - 2028 (USD Million)
11.3 Clinics
11.3.1 Market size, by region, 2017 - 2028 (USD Million)
11.4 Hemophilia Treatment Centers
11.4.1 Market size, by region, 2017 - 2028 (USD Million)
11.5 Others
11.5.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 12 Hemophilia Treatment Market, By Region
12.1 Key regional trends
12.2 North America
12.2.1 Market size, by country, 2017 - 2028 (USD Million)
12.2.2 Market size, by disease, 2017 - 2028 (USD Million)
12.2.2.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.2.2.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.2.3 Market size, by product, 2017 - 2028 (USD Million)
12.2.3.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.2.3.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.2.3.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.2.4 Market size, by patient, 2017 - 2028 (USD Million)
12.2.4.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.2.4.2 Market size, by adult, 2017 - 2028 (USD Million)
12.2.5 Market size, by treatment, 2017 - 2028 (USD Million)
12.2.6 Market size, by therapy, 2017 - 2028 (USD Million)
12.2.7 Market size, by drug class, 2017 - 2028 (USD Million)
12.2.8 Market size, by route of administration, 2017 - 2028 (USD Million)
12.2.9 Market size, by end-use, 2017 - 2028 (USD Million)
12.2.10 U.S.
12.2.10.1 Market size, by disease, 2017 - 2028 (USD Million)
12.2.10.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.2.10.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.2.10.2 Market size, by product, 2017 - 2028 (USD Million)
12.2.10.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.2.10.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.2.10.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.2.10.3 Market size, by patient, 2017 - 2028 (USD Million)
12.2.10.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.2.10.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.2.10.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.2.10.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.2.10.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.2.10.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.2.10.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.2.11 Canada
12.2.11.1 Market size, by disease, 2017 - 2028 (USD Million)
12.2.11.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.2.11.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.2.11.2 Market size, by product, 2017 - 2028 (USD Million)
12.2.11.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.2.11.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.2.11.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.2.11.3 Market size, by patient, 2017 - 2028 (USD Million)
12.2.11.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.2.11.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.2.11.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.2.11.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.2.11.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.2.11.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.2.11.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.3 Europe
12.3.1 Market size, by country, 2017 - 2028 (USD Million)
12.3.2 Market size, by disease, 2017 - 2028 (USD Million)
12.3.2.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.3.2.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.3.3 Market size, by product, 2017 - 2028 (USD Million)
12.3.3.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.3.3.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.3.3.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.3.4 Market size, by patient, 2017 - 2028 (USD Million)
12.3.4.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.3.4.2 Market size, by adult, 2017 - 2028 (USD Million)
12.3.5 Market size, by treatment, 2017 - 2028 (USD Million)
12.3.6 Market size, by therapy, 2017 - 2028 (USD Million)
12.3.7 Market size, by drug class, 2017 - 2028 (USD Million)
12.3.8 Market size, by route of administration, 2017 - 2028 (USD Million)
12.3.9 Market size, by end-use, 2017 - 2028 (USD Million)
12.3.10 Germany
12.3.10.1 Market size, by disease, 2017 - 2028 (USD Million)
12.3.10.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.3.10.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.3.10.2 Market size, by product, 2017 - 2028 (USD Million)
12.3.10.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.3.10.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.3.10.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.3.10.3 Market size, by patient, 2017 - 2028 (USD Million)
12.3.10.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.3.10.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.3.10.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.3.10.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.3.10.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.3.10.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.3.10.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.3.11 UK
12.3.11.1 Market size, by disease, 2017 - 2028 (USD Million)
12.3.11.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.3.11.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.3.11.2 Market size, by product, 2017 - 2028 (USD Million)
12.3.11.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.3.11.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.3.11.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.3.11.3 Market size, by patient, 2017 - 2028 (USD Million)
12.3.11.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.3.11.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.3.11.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.3.11.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.3.11.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.3.11.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.3.11.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.3.12 France
12.3.12.1 Market size, by disease, 2017 - 2028 (USD Million)
12.3.12.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.3.12.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.3.12.2 Market size, by product, 2017 - 2028 (USD Million)
12.3.12.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.3.12.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.3.12.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.3.12.3 Market size, by patient, 2017 - 2028 (USD Million)
12.3.12.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.3.12.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.3.12.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.3.12.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.3.12.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.3.12.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.3.12.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.3.13 Spain
12.3.13.1 Market size, by disease, 2017 - 2028 (USD Million)
12.3.13.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.3.13.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.3.13.2 Market size, by product, 2017 - 2028 (USD Million)
12.3.13.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.3.13.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.3.13.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.3.13.3 Market size, by patient, 2017 - 2028 (USD Million)
12.3.13.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.3.13.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.3.13.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.3.13.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.3.13.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.3.13.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.3.13.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.3.14 Italy
12.3.14.1 Market size, by disease, 2017 - 2028 (USD Million)
12.3.14.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.3.14.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.3.14.2 Market size, by product, 2017 - 2028 (USD Million)
12.3.14.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.3.14.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.3.14.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.3.14.3 Market size, by patient, 2017 - 2028 (USD Million)
12.3.14.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.3.14.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.3.14.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.3.14.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.3.14.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.3.14.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.3.14.8 Market size, by end-use, 2017 - 2028 (USD Million)



List of Tables

12.4 Asia Pacific
12.4.1 Market size, by country, 2017 - 2028 (USD Million)
12.4.2 Market size, by disease, 2017 - 2028 (USD Million)
12.4.2.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.4.2.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.4.3 Market size, by product, 2017 - 2028 (USD Million)
12.4.3.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.4.3.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.4.3.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.4.4 Market size, by patient, 2017 - 2028 (USD Million)
12.4.4.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.4.4.2 Market size, by adult, 2017 - 2028 (USD Million)
12.4.5 Market size, by treatment, 2017 - 2028 (USD Million)
12.4.6 Market size, by therapy, 2017 - 2028 (USD Million)
12.4.7 Market size, by drug class, 2017 - 2028 (USD Million)
12.4.8 Market size, by route of administration, 2017 - 2028 (USD Million)
12.4.9 Market size, by end-use, 2017 - 2028 (USD Million)
12.4.10 China
12.4.10.1 Market size, by disease, 2017 - 2028 (USD Million)
12.4.10.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.4.10.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.4.10.2 Market size, by product, 2017 - 2028 (USD Million)
12.4.10.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.4.10.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.4.10.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.4.10.3 Market size, by patient, 2017 - 2028 (USD Million)
12.4.10.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.4.10.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.4.10.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.4.10.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.4.10.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.4.10.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.4.10.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.4.11 Japan
12.4.11.1 Market size, by disease, 2017 - 2028 (USD Million)
12.4.11.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.4.11.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.4.11.2 Market size, by product, 2017 - 2028 (USD Million)
12.4.11.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.4.11.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.4.11.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.4.11.3 Market size, by patient, 2017 - 2028 (USD Million)
12.4.11.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.4.11.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.4.11.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.4.11.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.4.11.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.4.11.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.4.11.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.4.12 India
12.4.12.1 Market size, by disease, 2017 - 2028 (USD Million)
12.4.12.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.4.12.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.4.12.2 Market size, by product, 2017 - 2028 (USD Million)
12.4.12.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.4.12.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.4.12.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.4.12.3 Market size, by patient, 2017 - 2028 (USD Million)
12.4.12.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.4.12.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.4.12.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.4.12.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.4.12.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.4.12.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.4.12.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.4.13 Australia
12.4.13.1 Market size, by disease, 2017 - 2028 (USD Million)
12.4.13.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.4.13.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.4.13.2 Market size, by product, 2017 - 2028 (USD Million)
12.4.13.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.4.13.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.4.13.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.4.13.3 Market size, by patient, 2017 - 2028 (USD Million)
12.4.13.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.4.13.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.4.13.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.4.13.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.4.13.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.4.13.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.4.13.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.4.14 South Korea
12.4.14.1 Market size, by disease, 2017 - 2028 (USD Million)
12.4.14.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.4.14.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.4.14.2 Market size, by product, 2017 - 2028 (USD Million)
12.4.14.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.4.14.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.4.14.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.4.14.3 Market size, by patient, 2017 - 2028 (USD Million)
12.4.14.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.4.14.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.4.14.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.4.14.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.4.14.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.4.14.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.4.14.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.5 Latin America
12.5.1 Market size, by country, 2017 - 2028 (USD Million)
12.5.2 Market size, by disease, 2017 - 2028 (USD Million)
12.5.2.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.5.2.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.5.3 Market size, by product, 2017 - 2028 (USD Million)
12.5.3.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.5.3.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.5.3.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.5.4 Market size, by patient, 2017 - 2028 (USD Million)
12.5.4.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.5.4.2 Market size, by adult, 2017 - 2028 (USD Million)
12.5.5 Market size, by treatment, 2017 - 2028 (USD Million)
12.5.6 Market size, by therapy, 2017 - 2028 (USD Million)
12.5.7 Market size, by drug class, 2017 - 2028 (USD Million)
12.5.8 Market size, by route of administration, 2017 - 2028 (USD Million)
12.5.9 Market size, by end-use, 2017 - 2028 (USD Million)
12.5.10 Brazil
12.5.10.1 Market size, by disease, 2017 - 2028 (USD Million)
12.5.10.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.5.10.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.5.10.2 Market size, by product, 2017 - 2028 (USD Million)
12.5.10.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.5.10.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.5.10.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.5.10.3 Market size, by patient, 2017 - 2028 (USD Million)
12.5.10.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.5.10.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.5.10.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.5.10.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.5.10.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.5.10.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.5.10.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.5.11 Mexico
12.5.11.1 Market size, by disease, 2017 - 2028 (USD Million)
12.5.11.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.5.11.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.5.11.2 Market size, by product, 2017 - 2028 (USD Million)
12.5.11.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.5.11.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.5.11.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.5.11.3 Market size, by patient, 2017 - 2028 (USD Million)
12.5.11.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.5.11.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.5.11.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.5.11.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.5.11.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.5.11.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.5.11.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.5.12 Argentina
12.5.12.1 Market size, by disease, 2017 - 2028 (USD Million)
12.5.12.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.5.12.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.5.12.2 Market size, by product, 2017 - 2028 (USD Million)
12.5.12.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.5.12.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.5.12.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.5.12.3 Market size, by patient, 2017 - 2028 (USD Million)
12.5.12.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.5.12.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.5.12.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.5.12.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.5.12.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.5.12.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.5.12.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.6 Middle East and Africa
12.6.1 Market size, by country, 2017 - 2028 (USD Million)
12.6.2 Market size, by disease, 2017 - 2028 (USD Million)
12.6.2.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.6.2.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.6.3 Market size, by product, 2017 - 2028 (USD Million)
12.6.3.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.6.3.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.6.3.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.6.4 Market size, by patient, 2017 - 2028 (USD Million)
12.6.4.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.6.4.2 Market size, by adult, 2017 - 2028 (USD Million)
12.6.5 Market size, by treatment, 2017 - 2028 (USD Million)
12.6.6 Market size, by therapy, 2017 - 2028 (USD Million)
12.6.7 Market size, by drug class, 2017 - 2028 (USD Million)
12.6.8 Market size, by route of administration, 2017 - 2028 (USD Million)
12.6.9 Market size, by end-use, 2017 - 2028 (USD Million)
12.6.10 South Africa
12.6.10.1 Market size, by disease, 2017 - 2028 (USD Million)
12.6.10.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.6.10.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.6.10.2 Market size, by product, 2017 - 2028 (USD Million)
12.6.10.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.6.10.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.6.10.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.6.10.3 Market size, by patient, 2017 - 2028 (USD Million)
12.6.10.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.6.10.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.6.10.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.6.10.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.6.10.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.6.10.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.6.10.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.6.11 Saudi Arabia
12.6.11.1 Market size, by disease, 2017 - 2028 (USD Million)
12.6.11.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.6.11.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.6.11.2 Market size, by product, 2017 - 2028 (USD Million)
12.6.11.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.6.11.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.6.11.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.6.11.3 Market size, by patient, 2017 - 2028 (USD Million)
12.6.11.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.6.11.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.6.11.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.6.11.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.6.11.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.6.11.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.6.11.8 Market size, by end-use, 2017 - 2028 (USD Million)
12.6.12 UAE
12.6.12.1 Market size, by disease, 2017 - 2028 (USD Million)
12.6.12.1.1 Market size, by hemophilia A, 2017 - 2028 (USD Million)
12.6.12.1.2 Market size, by hemophilia B, 2017 - 2028 (USD Million)
12.6.12.2 Market size, by product, 2017 - 2028 (USD Million)
12.6.12.2.1 Market size, by recombinant factor concentrates, 2017 - 2028 (USD Million)
12.6.12.2.2 Market size, by plasma-derived factor concentrates, 2017 - 2028 (USD Million)
12.6.12.2.3 Market size, by extended half-life products, 2017 - 2028 (USD Million)
12.6.12.3 Market size, by patient, 2017 - 2028 (USD Million)
12.6.12.3.1 Market size, by pediatric, 2017 - 2028 (USD Million)
12.6.12.3.2 Market size, by adult, 2017 - 2028 (USD Million)
12.6.12.4 Market size, by treatment, 2017 - 2028 (USD Million)
12.6.12.5 Market size, by therapy, 2017 - 2028 (USD Million)
12.6.12.6 Market size, by drug class, 2017 - 2028 (USD Million)
12.6.12.7 Market size, by route of administration, 2017 - 2028 (USD Million)
12.6.12.8 Market size, by end-use, 2017 - 2028 (USD Million)
Chapter 13 Company Profiles
13.1 Competitive dashboard, 2021
13.2 Bayer Healthcare
13.2.1 Business overview
13.2.2 Financial data
13.2.3 Product landscape
13.2.4 Strategic outlook
13.2.5 SWOT analysis
13.3 Biogen
13.3.1 Business overview
13.3.2 Financial data
13.3.3 Product landscape
13.3.4 Strategic outlook
13.3.5 SWOT analysis
13.4 Biotest AG
13.4.1 Business overview
13.4.2 Financial data
13.4.3 Product landscape
13.4.4 Strategic outlook
13.4.5 SWOT analysis
13.5 CSL Behring
13.5.1 Business overview
13.5.2 Financial data
13.5.3 Product landscape
13.5.4 Strategic outlook
13.5.5 SWOT analysis
13.6 Ferring B.V.
13.6.1 Business overview
13.6.2 Financial data
13.6.3 Product landscape
13.6.4 Strategic outlook
13.6.5 SWOT analysis
13.7 Genentech
13.7.1 Business overview
13.7.2 Financial data
13.7.3 Product landscape
13.7.4 Strategic outlook
13.7.5 SWOT analysis
13.8 Kedrion
13.8.1 Business overview
13.8.2 Financial data
13.8.3 Product landscape
13.8.4 Strategic outlook
13.8.5 SWOT analysis
13.9 Novo Nordisk
13.9.1 Business overview
13.9.2 Financial data
13.9.3 Product landscape
13.9.4 Strategic outlook
13.9.5 SWOT analysis
13.10 Octapharma
13.10.1 Business overview
13.10.2 Financial data
13.10.3 Product landscape
13.10.4 Strategic outlook
13.10.5 SWOT analysis
13.11 Pfizer
13.11.1 Business overview
13.11.2 Financial data
13.11.3 Product landscape
13.11.4 Strategic outlook
13.11.5 SWOT analysis
13.12 Sanofi SA
13.12.1 Business overview
13.12.2 Financial data
13.12.3 Product landscape
13.12.4 Strategic outlook
13.12.5 SWOT analysis
13.13 Swedish Orphan Biovitrum AB
13.13.1 Business overview
13.13.2 Financial data
13.13.3 Product landscape
13.13.4 Strategic outlook
13.13.5 SWOT analysis